Xultophy 100/3.6
Insulin degludec and liraglutide · Novo Nordisk
PRESCRIPTION ONLY (USA)Xultophy 100/3.6 ingredients
| Active ingredient | Strength |
|---|---|
| Insulin Degludec | 100 [iU]/mL |
| Liraglutide | 3.6 mg/mL |
What Xultophy 100/3.6 is used for
Xultophy 100/3.6 is a specialist medicine (glp-1 receptor agonist, insulin analog). Its approved uses are listed on the official FDA label below.
Key facts
- Brand
- Xultophy 100/3.6
- Generic name
- Insulin degludec and liraglutide
- Made by
- Novo Nordisk
- Forms
- Injection, Solution
- Given
- Subcutaneous
- Drug class
- GLP-1 Receptor Agonist, Insulin Analog
- FDA approval
- Biologic licence (BLA) BLA208583
- On the US market since
- 2016
Official information
- Xultophy 100/3.6 prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Insulin degludec and liraglutide)
In India
- Insulin degludec: 5 brands in India
- Liraglutide: 2 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Xultophy 100/3.6?
Xultophy 100/3.6 (Insulin degludec and liraglutide) is a specialist medicine made by Novo Nordisk, approved by the US FDA.
What are the ingredients of Xultophy 100/3.6?
Xultophy 100/3.6 contains Insulin Degludec (100 [iU]/mL); Liraglutide (3.6 mg/mL).
From the FDA National Drug Code directory (open.fda.gov, public domain). Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA